Innocoll Holdings PLC (INNL) Downgraded by Zacks Investment Research to “Sell”

Innocoll Holdings PLC (NASDAQ:INNL) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Friday.

According to Zacks, “Innocoll Holdings develops and manufactures pharmaceutical products and medical devices through its proprietary collagen-based technologies. The company’s product include CollaGUARD(Ex-US), CollatampG(R), Septocoll(R), RegenePro(R), Collieva(R), CollaCare(R), Collexa(R) and Zorpreva(TM). It operates primarily in Asia, Australia, Canada, Europe, Latin America, the Middle East and the United States. Innocoll AG, formerly known as Innocoll GmbH, is headquartered in Athlone, Ireland. “

INNL has been the topic of a number of other research reports. JMP Securities upgraded Innocoll Holdings PLC to an “outperform” rating and set a $4.00 target price on the stock in a research note on Wednesday, March 29th. Stifel Nicolaus lowered Innocoll Holdings PLC from a “buy” rating to a “hold” rating and reduced their target price for the stock from $9.00 to $2.00 in a research note on Friday, March 17th. Finally, FBR & Co reiterated a “hold” rating on shares of Innocoll Holdings PLC in a research note on Thursday, April 6th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $3.75.

Innocoll Holdings PLC (NASDAQ INNL) opened at 2.17 on Friday. The stock has a 50 day moving average of $2.11 and a 200 day moving average of $1.58. Innocoll Holdings PLC has a one year low of $0.53 and a one year high of $12.94. The company’s market cap is $64.64 million.

ILLEGAL ACTIVITY WARNING: This piece was reported by Mideast Time and is owned by of Mideast Time. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be viewed at

Hedge funds have recently added to or reduced their stakes in the company. Alyeska Investment Group L.P. raised its stake in Innocoll Holdings PLC by 57.4% in the fourth quarter. Alyeska Investment Group L.P. now owns 837,626 shares of the specialty pharmaceutical company’s stock worth $578,000 after buying an additional 305,482 shares during the last quarter. Prudential PLC raised its stake in Innocoll Holdings PLC by 19.2% in the fourth quarter. Prudential PLC now owns 1,079,172 shares of the specialty pharmaceutical company’s stock worth $745,000 after buying an additional 173,833 shares during the last quarter. Finally, Goldman Sachs Group Inc. acquired a new stake in Innocoll Holdings PLC during the first quarter worth $224,000. Institutional investors and hedge funds own 42.88% of the company’s stock.

About Innocoll Holdings PLC

Innocoll Holdings Public Limited Company is a commercial-stage specialty pharmaceutical and medical device company with late-stage development programs. The Company operates through the segment of manufacture and sale of collagen-based pharmaceutical products. It utilizes collagen-based technology platform to develop its biodegradable and bioresorbable products and product candidates, which can be broken down by the body without the need for surgical removal or applied TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:INNL”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Get a free copy of the Zacks research report on Innocoll Holdings PLC (INNL)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Innocoll Holdings PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innocoll Holdings PLC and related companies with's FREE daily email newsletter.

Leave a Reply

© 2006-2017 Mideast Time.